Moon Min Kyong, Jeong In-Kyong, Jung Oh Tae, Ahn Hwa Young, Kim Hwan Hee, Park Young Joo, Jang Hak Chul, Park Kyong Soo
Department of Internal MedicineSeoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of KoreaDepartment of Internal MedicineBoramae Medical Center, Seoul 156-707, Republic of KoreaDepartment of Internal MedicineChung-Ang University Hospital, College of Medicine, Chung-Ang University, Seoul 156-755, Republic of KoreaClinical Research InstituteSeoul National University Hospital, Seoul 110-74, Republic of KoreaDepartment of Internal MedicineSeoul National University Bundang Hospital, Seongnam 463-707, Republic of Korea Department of Internal MedicineSeoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of KoreaDepartment of Internal MedicineBoramae Medical Center, Seoul 156-707, Republic of KoreaDepartment of Internal MedicineChung-Ang University Hospital, College of Medicine, Chung-Ang University, Seoul 156-755, Republic of KoreaClinical Research InstituteSeoul National University Hospital, Seoul 110-74, Republic of KoreaDepartment of Internal MedicineSeoul National University Bundang Hospital, Seongnam 463-707, Republic of Korea.
Department of Internal MedicineSeoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of KoreaDepartment of Internal MedicineBoramae Medical Center, Seoul 156-707, Republic of KoreaDepartment of Internal MedicineChung-Ang University Hospital, College of Medicine, Chung-Ang University, Seoul 156-755, Republic of KoreaClinical Research InstituteSeoul National University Hospital, Seoul 110-74, Republic of KoreaDepartment of Internal MedicineSeoul National University Bundang Hospital, Seongnam 463-707, Republic of Korea.
J Endocrinol. 2015 Jul;226(1):35-42. doi: 10.1530/JOE-14-0714. Epub 2015 May 13.
Bisphenol A (BPA) is a widely used endocrine disruptor. Recent epidemiologic results have suggested an association between exposure to BPA and cardiovascular disease, type 2 diabetes, and obesity. We investigated the in vivo effects of long-term oral exposure to BPA on insulin resistance and glucose intolerance. In the present study, 4- to 6-week-old male mice on a high-fat diet (HFD) were treated with 50 μg/kg body weight per day of BPA orally for 12 weeks. Long-term oral exposure to BPA along with an HFD for 12 weeks induced glucose intolerance in growing male mice. Intraperitoneal glucose tolerance tests showed that the mice that received an HFD and BPA exhibited a significantly larger area under the curve than did those that received an HFD only (119.9±16.8 vs. 97.9±18.2 mM/min, P=0.027). Body weight, percentage of white adipose tissue, and percentage of body fat did not differ between the two groups of mice. However, treatment with BPA reduced Akt phosphorylation at position Thr308 and GSK3β phosphorylation at position Ser9 in skeletal muscle. BPA tended to decrease serum adiponectin levels and to increase serum interleukin 6 and tumor necrosis factor α, although these findings were not statistically significant. Treatment with BPA did not induce any detrimental changes in the islet area or morphology or the insulin content of β cells. In conclusion, long-term oral exposure to BPA induced glucose intolerance and insulin resistance in growing mice. Decreased Akt phosphorylation in skeletal muscle by way of altered serum adipocytokine levels might be one mechanism by which BPA induces glucose intolerance.
双酚A(BPA)是一种广泛使用的内分泌干扰物。最近的流行病学结果表明,接触BPA与心血管疾病、2型糖尿病和肥胖之间存在关联。我们研究了长期口服BPA对胰岛素抵抗和葡萄糖耐量的体内影响。在本研究中,对4至6周龄的高脂饮食(HFD)雄性小鼠每天口服50μg/kg体重的BPA,持续12周。长期口服BPA并结合HFD持续12周会导致生长中的雄性小鼠出现葡萄糖耐量异常。腹腔葡萄糖耐量试验表明,接受HFD和BPA的小鼠曲线下面积显著大于仅接受HFD的小鼠(119.9±16.8 vs. 97.9±18.2 mM/min,P=0.027)。两组小鼠的体重、白色脂肪组织百分比和体脂百分比没有差异。然而,BPA处理降低了骨骼肌中Akt在Thr308位点的磷酸化以及GSK3β在Ser9位点的磷酸化。BPA倾向于降低血清脂联素水平,并增加血清白细胞介素6和肿瘤坏死因子α,尽管这些结果没有统计学意义。BPA处理未引起胰岛面积、形态或β细胞胰岛素含量的任何有害变化。总之,长期口服BPA会导致生长中的小鼠出现葡萄糖耐量异常和胰岛素抵抗。通过改变血清脂肪细胞因子水平降低骨骼肌中的Akt磷酸化可能是BPA诱导葡萄糖耐量异常的一种机制。